Trial Profile
A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib-maintenance therapy in Flt3-ITD positive AML in complete hematological remission after allogenic stem cell transplantation.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2020
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms Sormain
- 16 Jul 2020 Primary endpoint (Relapse free survival (RFS)) has not been met.
- 16 Jul 2020 Results published in the Journal of Clinical Oncology
- 06 Dec 2018 Status changed from recruiting to discontinued.